Keith Lerro, MD, PhD, is a board certified oncologist and hematologist dedicated to using the latest treatments available against all types of cancer, even the most complex. Dr. Lerro received his cancer training at Yale University, residency at Montefiore, Albert Einstein College of Medicine, and his MD from Albert Einstein College of Medicine.
Jimmy Ruiz, MD, is a medical thoracic oncologist at the Wake Forest Comprehensive Cancer Center. He has written and contributed to numerous publications, and has a number of clinical trials in the space of immunotherapy for lung cancer at both the cancer center and Virginia.
Martin Palmeri, MD, is a medical oncologist specializing in melanoma and gastrointestinal cancers at the Cancer Center of Western North Carolina and lead of GI medical oncology research for the Mission Cancer Program. He is passionate about understanding and working with financial barriers to healthcare and the impact of healthcare policy. Dr. Palmeri has received several awards, including Dartmouth's Outstanding Physician Role Model Award and the American Medical Association Foundation's Excellence in Medicine Award.
Justin P. Favaro, MD, PhD, is the principal investigator for clinical cancer trials with the Novant Oncology Research Institute. His research experience includes both basic science work in viral replication and tumor growth, and clinical research focused on the role of angiogenesis inhibitors in colorectal cancer treatment. His interests include clinical care of patients with cancer and blood disorders.
Dr. Favaro has been named on the Top Doctors in Hematology/Oncology by Charlotte Magazine. He is a member of the Community Oncology Alliance, American Society of Hematology, and the American Society of Clinical Oncology.
Matthew Foster, MD, is assistant professor of clinical research for the leukemia, lymphoma, and myeloma program. His research interests involve clinical and translational research in the hematologic malignancies. In particular, he is involved in the design and conduct of phase I and II clinical trials of novel agents and drug combinations for patients with acute leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. Furthermore, Dr. Foster has particular interest in incorporating correlative science studies that can predict biologic response or drug toxicity in patients with hematologic cancers, including both host and tumor genetic variables that predict response to antileukemic agents.
Vinay Gudena, MD, is a medical oncologist who specializes in the treatment of breast cancers, and is also the director of cancer research for the Cone Health System.
He serves as a local principal investigator for a number of clinical trials. Dr. Gudena came to Greensboro from Ohio where he worked for University Hospitals of Cleveland. He was awarded master faculty for excellence in teaching, and helped start Firelands Regional Medical Center's breast program in addition to serving as the interim medical director of the oncology program.